FDA Approval
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Eisai
PR-M09-18-NI-070Sep 24, 2018
Study Results
Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease
Eisai
PR-M07-18-NI-103Jul 31, 2018
Drug Discovery
Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts
Eisai
PR-M06-18-NI-044Jun 13, 2018
Strategic Collaboration
Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
Eisai
PR-M03-18-NI-046Mar 13, 2018
Breakthrough Therapy
Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy
Eisai
PR-M01-18-NI-032Jan 12, 2018